'Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug' -STAT News
Portfolio Pulse from Benzinga Newsdesk
Senator Dick Durbin has accused Amgen (AMGN) of prioritizing profits over patient care by recommending a higher-than-necessary dose for its cancer drug, Lumakras. Durbin's allegations suggest that Amgen's dosing recommendations are not in the best interest of patients, potentially leading to higher costs and increased side effects without additional benefits. This criticism comes amid broader concerns over drug pricing and pharmaceutical practices.
May 14, 2024 | 6:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amgen faces criticism from Senator Durbin for allegedly recommending higher doses of Lumakras than necessary, potentially affecting the company's reputation and sparking concerns over its pricing and patient care practices.
The accusation by a high-profile lawmaker can lead to negative public perception and potential regulatory scrutiny for Amgen. This could affect the sales of Lumakras, impact Amgen's reputation in the market, and possibly lead to investigations or changes in pricing strategies. The immediate reaction could be negative sentiment among investors, potentially leading to a short-term decline in stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 90